Results 201 to 210 of about 22,830 (227)
Some of the next articles are maybe not open access.
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells
Investigational New Drugs, 2021Human T cell leukemia virus type 1 (HTLV-1) is responsible for adult T cell leukemia (ATL); however, molecular and cellular mechanisms underlying HTLV-1-induced leukemogenesis are unclear. BCL6 oncogene is involved in cancer progression and a preferred target of anti-cancer treatments.
Chie Ishikawa, Naoki Mori
openaire +2 more sources
The role of BCL6 in lymphomas and routes to therapy
British Journal of Haematology, 2010SummaryBCL6 is a transcription factor that has essential B‐cell and T‐cell roles in normal antibody responses. It is involved in chromosomal translocations in diffuse large B‐cell lymphoma (DBCL; including primary mediastinal B‐cell lymphoma) and nodular lymphocyte predominant Hodgkin lymphoma, and is expressed in follicular lymphoma and Burkitt's ...
Wagner, SD, Ahearne, M, Ko Ferrigno P
openaire +3 more sources
Bcl2‐negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression
Pathology International, 2007Bcl2 is an important protein involved in the pathogenesis of follicular lymphoma (FL). However, approximately 10% of FL cases do not express Bcl2. The present study was designed to compare gene aberrations, prosurvival gene expression, apoptosis and proliferation rates in Bcl2‐positive and ‐negative FL cases.
Ying, Guo +8 more
openaire +2 more sources
BCL6 Inhibitors Exhibit Therapeutic Effects on Breast Cancer Cells through the BCL6-STAT4 Pathway
Anti-Cancer Agents in Medicinal ChemistryObjective: This study aimed to explore the roles of BCL6 and STAT4 in breast cancer, their biological functions, and their relationships with the prognosis of patients with breast cancer. Methods: Online databases were used to analyze the expression characteristics of BCL6 and STAT4 in breast cancer, as well as the correlation between STAT4 and both
Zai, Wang +4 more
openaire +2 more sources
Division of labor for oncogene BCL6
Blood, 2007In this issue of Blood , Parekh and colleagues provide the first evidence that BCL6 uses different corepressor proteins for different functions. BCL6 requires the Mta3 corepressor to control B-cell differentiation, but not to control cell proliferation and survival.
openaire +1 more source
BCL6 controls contact-dependent help delivery during follicular T-B cell interactions
Immunity, 2021Dan Liu, Bo Liu, Ye Li
exaly
Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (TFH)
Trends in Immunology, 2021Jinyong Choi, Shane Crotty
exaly
ACS Medicinal Chemistry Letters
BCL6 overexpression drives lymphomagenesis and immune evasion in B-cell malignancies. This Patent Highlight presents novel bifunctional degraders targeting BCL6, demonstrating high potency and selectivity. These degraders induce BCL6 degradation via a PROTAC-based mechanism, resulting in apoptosis and tumor regression in BCL6-positive cancers.
openaire +2 more sources
BCL6 overexpression drives lymphomagenesis and immune evasion in B-cell malignancies. This Patent Highlight presents novel bifunctional degraders targeting BCL6, demonstrating high potency and selectivity. These degraders induce BCL6 degradation via a PROTAC-based mechanism, resulting in apoptosis and tumor regression in BCL6-positive cancers.
openaire +2 more sources
Roles of BCL6 in normal and transformed germinal center B cells
Immunological Reviews, 2012Katia Basso, Riccardo Dalla-Favera
exaly